Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Congenital neutropenias.

Cornelia Zeidler1, Beate Schwinzer, Karl Welte

  • 1Department for Pediatric Hematology/Oncology, Kinderklinik Medizinische Hochschule Hannover, Carl-Neuberg-Str. 1, 30625 Hannover. Zeidler.Cornelia@mh-hannover.de

Reviews in Clinical and Experimental Hematology
|December 25, 2003
PubMed
Summary

Congenital neutropenia (CN) is a severe condition causing low neutrophil counts and increased infections. Recombinant human granulocyte-colony stimulating factor (rHuG-CSF) effectively treats most CN patients, though risks like malignancy exist.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Diagnosis and management of neutropenia in adults: Expert guidance.

British journal of haematology·2026
Same author

Inherited disorders of granulopoiesis: understanding pathogenesis to advance new therapies.

Experimental hematology·2026
Same author

Targeted inhibition of <i>ELANE</i> expression using adenine base editing to treat severe congenital neutropenia.

Molecular therapy. Methods & clinical development·2025
Same author

In memoriam: Malcom A.S. Moore (1944-2025).

Leukemia·2025
Same author

Tuning of G-CSFR signaling by de novo-designed agonists.

Molecular therapy : the journal of the American Society of Gene Therapy·2025
Same author

NAMPT-mediated deacetylation of HCLS1 protein promotes clonogenic growth of pediatric CML cells.

Experimental hematology·2025

Area of Science:

  • Hematology
  • Genetics
  • Immunology

Background:

  • Congenital neutropenia (CN) encompasses disorders with severe neutropenia (ANC < 0.5 x 10^9/L), increasing bacterial infection susceptibility.
  • CN includes primary bone marrow failure, metabolic/immunologic disorders, and complex syndromes.
  • We advocate reserving 'CN' for severe neutropenia with myelopoiesis arrest, historically Kostmann syndrome.

Purpose of the Study:

  • To clarify the definition and scope of congenital neutropenia.
  • To analyze treatment responses and adverse events in a large patient cohort.

Main Methods:

  • Analysis of data from over 400 patients in the Severe Chronic Neutropenia International Registry.
  • Review of genetic mutations, including neutrophil elastase and G-CSF receptor genes.

Related Experiment Videos

  • Assessment of treatment outcomes with recombinant human granulocyte-colony stimulating factor (rHuG-CSF).

    • Main Results:

    • Over 90% of CN patients responded to rHuG-CSF, maintaining ANC around 1.0 x 10^9/L.
    • Adverse events included splenomegaly, thrombocytopenia, osteoporosis, and malignant transformation.
    • Genetic aberrations like monosomy 7 and ras mutations correlated with increased malignancy risk.

    Conclusions:

    • rHuG-CSF is a highly effective treatment for most congenital neutropenia subtypes.
    • Long-term risks include potential for myelodysplastic syndrome/leukemia, possibly linked to genetic instability.
    • Hematopoietic stem cell transplantation remains the alternative for G-CSF refractory cases.